Skip to content

To evaluate the Safety and efficacy of Unani formulations in Commom Cold

Validation of Unani Pharmacopoeial formulation- Habb-e- Shifa for symptomatic relief in patients of Nazla-e- HÄ?r (Common Cold)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/12/004257
Enrollment
540
Registered
2013-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00- Acute nasopharyngitis [common cold] Health Condition 2: null- Nazla-e- HÄ?r (Common Cold)

Interventions

Intervention1: Habb-e- Shifa: 1-2 Pills, orally two times daily after breakfast and dinner. one Pill for patients weighing up to 50 kg and two Pills pills for patients weighing more than 50 kg. Contro

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All subjects should meet the following criteria: 1- Patients of either sex in the age group of 18-65 2- Patients of Nazla-e- HÄ?r (Common Cold) presenting with recent onset of any of the following symptoms: • KhushÅ«na al-Halaq (Sore throat) • Buhha al-Sawt (Hoarseness of Voice) • â??UtÄ?s (Sneezing/ Nasal irritation) • SudÄ?â?? (Headache) • Suâ??Ä?l (Cough) • Runny nose • Iâ??yÄ? (Malaise) • Flushing of Face • With or without low grade fever (

Exclusion criteria

Exclusion criteria: Patients will be excluded if they meet any of the following criteria: 1. Patients of acute or chronic lower respiratory tract infection like pneumonia, Bronchitis, Asthma and Bronchiectasis. 2. Fever 102oF 3. Known cases of any other acute illness 4. Pregnant and lactating women 5. Known case of Renal/ Hepatic/ Cardiac impairment or the ailment needs long term therapy

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptoms of Nazla-e- HÄ?r (Common Cold) Timepoint: 1 week

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: 1 WEEK

Countries

India

Contacts

Public ContactDR ABDUL HANNAN

Central Council for Research in Unani Medicine (CCRUM),

ccrum605@gmail.com01128521981

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026